Company Overview
More
Sansheng Pharmaceutical is an investment holding company mainly engaged in the development, production, marketing and sales of pharmaceutical products. The company's main products include recombinant human thrombopoietin products, tumor necrosis factor-α inhibitors and recombinant human erythropoietin. The products are sold under the brands of Tebio, Yisep, iBio, and Cyber. The company sells products in the domestic market and overseas markets such as Sri Lanka, the Dominican Republic and Thailand. The company's subsidiaries include Jisi Co., Ltd., Hong Kong Sansheng Medical Co., Ltd. And Shenyang Sansheng Pharmaceutical Co., Ltd. The company is also engaged in project management and consulting through its subsidiaries.
CEO： Jing Lou
Market： Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
01530 3SBIO
5.710+0.090+1.60%
YOY
Do not show
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Assets
Current assets
Inventory
11.46%
690.52M
19.59%
681.5M
17.23%
619.51M
26.71%
569.88M
Accounts receivable
40.27%
1.38B
3.53%
1.22B
-3.47%
982.97M
-23.61%
1.18B
Advance deposits and other receivables
30.75%
768.73M
15.41%
582.66M
24.46%
587.92M
-33.25%
504.85M
Cash and equivalents
-7.21%
2.87B
-23.03%
2.92B
48.39%
3.09B
174.88%
3.79B
Secured deposit
46.71%
184.59M
403.8%
111.86M
470.03%
125.82M
47.99%
22.2M
Financial assets at fair value-current assets
49.27%
1.9B
135.44%
1.88B
169.58%
1.27B
-15.87%
799.32M
Total current assets
16.63%
7.79B
7.71%
7.4B
45.34%
6.68B
34.77%
6.87B
Non-current assets
Property, plant and equipment
31.24%
3.44B
44.95%
3.04B
31.81%
2.62B
15.35%
2.1B
Advance payment
-8.23%
298.84M
--
--
--
325.63M
--
--
Long-term receivables
--
--
--
--
-66.44%
2.2M
-59.95%
3.58M
Associated company interest
-7.06%
696.82M
29.06%
748.61M
26.34%
749.72M
51.26%
580.05M
Interests in Joint Venture
-45.76%
3.77M
-25.51%
5.67M
-7.03%
6.95M
33.73%
7.61M
Financial assets at fair value-non-current assets
-30.86%
620.68M
--
--
--
897.72M
--
--
Other investments
--
--
--
--
--
--
45.26%
929.66M
Intangible assets
-2.6%
1.85B
-12.62%
1.85B
-12.32%
1.9B
-5.25%
2.12B
Goodwill
-1.91%
3.84B
-7.42%
3.89B
-5.47%
3.92B
2.52%
4.2B
Deferred tax assets
27.91%
280.48M
49.8%
228.49M
69.95%
219.28M
18.37%
152.53M
Special items of non-current assets
8.39%
388.04M
114.18%
1.38B
-28.38%
358.01M
33.19%
642.82M
Total non-current assets
3.85%
11.42B
3.8%
11.14B
7.69%
11B
9.51%
10.73B
Total assets
8.68%
19.21B
5.33%
18.54B
19.37%
17.68B
18.15%
17.6B
Liabilities
Current liabilities
Accounts payable
13.34%
230.41M
29.33%
214.95M
35.74%
203.29M
-2.62%
166.2M
Tax payable
27.93%
73.71M
-17.37%
84.09M
170.06%
57.62M
49.65%
101.77M
Other payables and accrued expenses
17.09%
921.21M
-4.15%
842.35M
-13.92%
786.75M
-4.28%
878.81M
Bank loans and overdrafts
-58.3%
150.19M
-67.36%
150.13M
-25.58%
360.15M
-60.68%
460M
Financial lease liabilities-current liabilities
50.76%
10.56M
24.6%
9.29M
28.17%
7.01M
--
7.46M
Deferred income-current liabilities
-6.11%
33.91M
-7.99%
34.16M
-2.97%
36.11M
1.55%
37.12M
Total current liabilities
-2.13%
1.42B
-19.16%
1.33B
-9.98%
1.45B
-30.12%
1.65B
Net current assets
21.83%
6.37B
16.21%
6.07B
75.21%
5.23B
90.83%
5.22B
Total assets less current liabilities
9.65%
17.79B
7.86%
17.21B
22.96%
16.23B
27.25%
15.95B
Non-current liabilities
Long-term bank loan
207.88%
164.15M
377.51%
64.63M
301.29%
53.32M
-90.37%
13.53M
Financial lease liabilities-non-current liabilities
0.5%
32.38M
23.94%
33.6M
712.79%
32.22M
407.11%
27.11M
Deferred tax liability
-2.86%
264.47M
-2.96%
266.19M
1.55%
272.24M
2.25%
274.33M
Deferred income-non-current liabilities
28.58%
396.63M
38.68%
319.4M
27.3%
308.46M
-12.77%
230.31M
Convertible notes and bonds
-7.71%
2.27B
-38.88%
2.39B
6.8%
2.46B
70.03%
3.91B
Other non-current liabilities
-11.28%
5.57M
4.47%
6.05M
6.97%
6.28M
-5.85%
5.79M
Total non-current liabilities
0.03%
3.13B
-30.96%
3.08B
10.42%
3.13B
49.49%
4.46B
Total liabilities
-0.66%
4.55B
-27.77%
4.41B
3.03%
4.58B
14.29%
6.11B
Total assets less total liabilities
11.95%
14.66B
22.92%
14.13B
26.39%
13.09B
20.31%
11.49B
Total equity and non-current liabilities
9.65%
17.79B
7.86%
17.21B
22.96%
16.23B
27.25%
15.95B
Equity
Share capital
0%
155K
0.65%
156K
0%
155K
0%
155K
Share premium
-3.39%
4.15B
1.03%
4.34B
-0.23%
4.3B
-0.23%
4.3B
Other reserves
26.35%
8.08B
15.86%
7.39B
20.2%
6.39B
38.31%
6.38B
Shareholders' Equity
14.39%
12.23B
9.89%
11.73B
11.06%
10.69B
19.7%
10.68B
Non-controlling interest
1.1%
2.43B
193.09%
2.4B
227.4%
2.4B
28.95%
817.54M
Total equity
11.95%
14.66B
22.92%
14.13B
26.39%
13.09B
20.31%
11.49B
Total equity and total liabilities
8.68%
19.21B
5.33%
18.54B
19.37%
17.68B
18.15%
17.6B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
Unqualified Opinion--Unqualified Opinion--
Auditor
Ernst & Young accounting firm--Ernst & Young accounting firm--
Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.
The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%